Psoriasis, a condition that manifests with itchy raised areas of red skin that often scale and flake, has been found to affect more than 8 million people in the US. These red, scaly bumpy growths of skin often appear on the scalp, knees, elbows, face or other parts of the body and are often quite painful. Many patients suffer most from the appearance of plaque psoriasis, feeling rejected or distanced by other people afraid of this non-contagious skin disease.

Newer treatments called biologics are restricted for use for about 25% of Psoriasis patients with extreme manifestations of the disease. Only about 6% of psoriasis patients use biologic treatments. These treatments involve injections and can have severe side affects as these treatments lower the ability of your immune system to fight off other disease.

Topical treatments for psoriasis are used by about 90% of patients. There has been no new mechanism of action for topical treatment of psoriasis for over 20 years. Just recently new studies have shown promise for a new medication for the topical treatment of psoriasis.

The New England Journal of Medicine has published in its July 2020 issue that a new topical cream called Roflumilast has shown positive results in treatment of plaque psoriasis. Patients with moderate psoriasis treated with a 0.3% cream or a 0.15% cream experienced an almost clear condition after 6 weeks of treatment (28% and 23% of patients respectively). Patients with mild cases of psoriasis experienced a clear state of skin after 12 weeks of use the 0.3% cream (93% of these cases). Ninety-seven percent of adverse reactions were rated mild or moderate in severity.

These initial test results show positive potential for a new and effective once-daily topical treatment for psoriasis patients with mild to moderate cases of the disease. The product seems well tolerated and is significantly successful in reducing or removing psoriasis without injections or immunity suppression.

Dr. Moore and her research team are enrolling patients in Arcutis Clinical Trials for this new topical treatment of psoriasis. This same medication is being tested with other inflammatory skin conditions such as Seborrheic Dermatitis and Atopic Dermatitis. Please contact our Clinical Trials (click here) department if you or someone you know might be a candidate for this free treatment. Contact us at 817-795-7546 extension 339
(Source New England Journal of Medicine, July 2020)